I. Synthetic polymer-based anticancer prodrugsJindrich Kopecek (Departments of Pharmaceutics and Pharmaceutical Chemistry and of Bioengineering, University of Utah, Salt Lake City, Utah 84112) HPMA-anticancer drug conjugatesRichard B. Greenwald (Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, New Jersey 00854)Poly(ethylene glycol)-anticancer drug conjugatesChun Li (Department of Experimental Diagnostic Imaging, Box 59, The University of Texas, M.D. Anderson Cancer Center,1515 Holcombe Blvd., Houston, TX 77030, USA)Poly(L-glutamic acid)-anticancer drug conjugatesII. Natural polymer-based anticancer prodrugsFelix Kratz (Department of Medical Oncology, Clinical Research, Tumor Biology Center, Breisacher Straße 117, D-79106 Freiburg, Federal Republic of Germany) Protein-based anticancer conjugatesAndrew V. Schally (Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New Orleans, Louisiana)Peptide and peptide hormone anticancer therapeuticsYoshiharu Machida (Department of Drug Delivery Research, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan)Chitosan and other polysaccharide anticancer conjugatesIII. Antibody-directed cancer therapyJohn R. DesjarlaisXencor, Inc. CA 91016, United StatesEngineering of antitumor antibodiesVictor S. Goldmacher (ImmunoGen Inc., 128 Sidney Street, Cambridge, MA 02139-4239, USA)Antibody-anticancer drug conjugatesDavid M. Goldenberg (Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA.)Immunoconjugate and radioimmunoconjugate anticancer therapeutics Kenneth D. Bagshawe (Imperial College London, Department of Medical Oncology, Charing Cross Campus, Fulham Palace Road, London W6 8RF, UK.)Antibody-directed enzyme prodrug anticancer therapeutics Paul M. Harari (University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, WI 53792, USA.)EGFR-directed monoclonal antibodiesGabriel N. Hortobagyi (Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX. usa)Her2/neu-directed antibodies John M. Kirkwood (Division of Hematology-Oncology, Department of Medicine, Hillman Cancer Center, Pittsburgh, PA 15232)CTLA-4-directed monoclonal antibodiesDario Neri (Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland)Antibodies directed to tumor vasculatureIV. Lipid-based anticancer prodrugsL. Harivardhan Reddy, Patrick Couvreur (Physicochimie, Pharmacotechnie et Biopharmacie, Faculty of Pharmacy, Universite Paris-Sud XI, Chatenay-Malabry, France)Lipid-based prodrugs of anti-metabolite anticancer agentsMitsuru Hashida (Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan)Lipid-based prodrugs of non-anti-metabolite anticancer agentsV. Macromolecular nucleic acid therapeuticsErnst Wagner (Pharmaceutical Biology-Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universitaet, Butenandtstr. 5-13, D-81377, Muenchen, Germany)Macromolecular nucleic acid therapeuticsUwe Zangemeister-Wittke (Department of Pharmacology, University of Bern, Bern, Switzerland.)Antisense oligonucleotidesBrett P. Monia (Isis Pharmaceuticals, California 92008, USA)Therapeutic MicroRNAsMark A. Behlke (Integrated DNA Technologies Inc., Coralville, IA 52241, USA)Therapeutic siRNAs... Mehr
Preis-Alarm
